Did Cryoport's 77% Run Pass You By? What The Bulls Got Right

Cryoport looked like a niche logistics specialist at the start of 2026, tied closely to the fortunes of cell and gene therapies and facing debate over whether cold chain expansion or regulatory friction would matter more. Investors who held Cryoport from the start of the year are up 76.8%, including dividends. If you were weighing those bullish growth assumptions against bearish worries about commoditization and client setbacks, which signals would have tipped your decision?

The useful thing about a Narrative is that the reasoning is checkable: the assumptions sit beside the argument, and together they imply an estimated Fair Value you can disagree with.

The easy part of this move is behind Cryoport. Zero in on 27 high quality undervalued stocks for companies trading below our estimates.

The Two Cryoport Stories Investors Had To Weigh

The shares cost US$9.6 at the start of the period, and Cryoport sat between two sharply different but plausible stories about its future.

On the bullish side, the cold chain expansion narrative put Fair Value at US$12.11, based on cell and gene therapy demand and a revenue decline assumption of 4.7% each year, with profit margins reaching 14.2% and a future P/E of 27.2x.

The more cautious view set Fair Value at US$8, assumed revenue would fall 6.7% a year, and focused on regulatory tightening and potential commoditization that could affect Cryoport's pricing power, even if margins eventually reached 14.2% on a future P/E of 19.2x.

What The Results Changed For Cryoport

The clearest new fact was Cryoport’s Q2 2026 report. Revenue moved from US$45.454m in Q2 2025 to US$48.971m in Q2 2026. The business still reported a loss, although net income improved from a loss of US$14.014m to a smaller loss of US$10.255m and net margin rose from -30.8% to -20.9%. The evidence cut both ways.

The original debate hinged on whether cold chain expansion would translate into healthier earnings. For a different stock, you would test that same claim by tracking revenue against the direction of net income and the trend in net margin in each set of results.

What Cryoport’s Run Now Asks You To Believe

Cryoport trades at US$16.9 today, after a 76.8% gain from the start of the year. The selected Narrative’s Fair Value sits below the current price, reflecting a view that the recent climb already bakes in demanding expectations.

The Narrative turns on whether high fixed costs, customer concentration, and possible commoditization stay manageable as cell and gene therapy logistics mature. A buyer at today’s price must judge that service margins can hold up even if therapy methods change or trial activity cools.

"Although Cryoport benefits from the increasing complexity and sensitivity of biologics, making its services indispensable and supporting gross margin expansion, the emergence of industry standardization and potential commoditization in biopharma logistics could erode differentiation and place downward pressure on margins over time."

One Narrative has put a figure on that disagreement. → See the Narrative with its lower Fair Value, assumptions and all

Find Your Own Contrarian Opportunity

By the time a rally makes headlines, you are reading about returns someone else has already earned. Why not go straight to the source and look for your own contrarian opportunity? These three companies trade below our estimated value.

• Company 1 - 34% below our estimate - converts a record backlog of modular data center work into installations.
• Company 2 - 43% below our estimate - addresses complex testing, regulatory and AI-related risks for under-resourced clients.
• Company 3 - 37% below our estimate - builds critical e-infrastructure supporting hyperscale data centers and large manufacturing projects.

Three companies from the same screener. Open all 25 companies with the balance sheet to back it up →

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com